JI Ming
Ji Ming graduated from Peking University, and then got a master's degree in molecular biology and biochemistry and doctoral degree in pharmacology from PUMC. He had over 10 years of experience in drug R&D. He once worked with Pfizer for more than 5 years. Dr. Ji joined the Institute of Material Medica, CAMS in 2013 and focused on cancer pharmacology and early development of drugs. He is expecting to find out the potential targets in cancers and their mechanism. Exploring the biomarkers for antitumor drugs under development is also his interest. He is especially eager to establish some unique platforms to accelerate drug early development. Ji Ming has published more than 20 research papers and filed a number of patents related to drug substance. He has also received some national and academic grants.
1. A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models. Acta Pharmaceutica Sinica B. 2021 online.
2. Design, Synthesis, and Biological Evaluation of a Novel Photocaged PI3K Inhibitor toward Precise Cancer Treatment. J. Med. Chem. 2021 online.
3. Sphingosine-1-Phosphate Receptor Subtype 1 (S1P1) Modulator IMMH001 Regulates Adjuvant- and Collagen-Induced Arthritis. Front Pharmacol. 2019,10:1085.
4. CAT3, a prodrug of 13a(S)-3-hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine, circumvents temozolomide-resistant glioblastoma via the Hedgehog signaling pathway, independently of O6-methylguanine DNA methyltransferase expression. Onco Targets Ther. 2018, 11:3671-3684.
5. The Development of a Biotinylated NAD+-Applied Human Poly(ADP-Ribose) Polymerase 3 (PARP3) Enzymatic Assay. SLAS Discov. 2018, 23(6):545-553.
6. Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity. Org Biomol Chem. 2018, 16:3189.
7. Validating a Selective S1P1 Receptor Modulator Syl930 for Psoriasis Treatment. Biol Pharm Bull. 2018,41(4):592-596.
8. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer. Biochem Pharmacol. 2016, 107:29-40.
9. Discovery of novel quinazoline-2,4(1H,3H)-dione derivatives as potent PARP-2 selective inhibitors. Bioorg Med Chem. 2017, 25(15):4045-4054.
10. Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity. Eur J Med Chem. 2017, 132:26-41.
11. Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors. Bioorg Med Chem. 2015, 23(4):681-93.
